Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Julie Silber , Senior Director of Investor Relations has stepped down from her position to pursue other
| LUND Sweden, Dec. 7, 2020 /PRNewswire/ --Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Julie Silber, Senior Director of Investor Relations has stepped down from her position to pursue other opportunities effective November 30, 2020. CEO, Patrik Dahlen will assume the Investor Relations duties immediately. “We appreciate the many contributions Julie made since joining the Immunovia team as Director of IR. We would like to thank Julie for her time at Immunovia,” stated Patrik Dahlen, CEO of Immunovia. For more information, please contact: About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. This information was brought to you by Cision http://news.cision.com https://news.cision.com/immunovia-ab/r/immunovia-announces-investor-relations-changes,c3250432 The following files are available for download:
SOURCE Immunovia AB | ||||
Company Codes: Bloomberg:IMMNOV@SS, ISIN:SE0006091997, RICS:IMMNOV.ST, Stockholm:IMMNOV |
View original content:
